• Login
    View Item 
    •   Plemochoe Home
    • Articles / Άρθρα
    • School of Medicine
    • Department of Medicine
    • View Item
    •   Plemochoe Home
    • Articles / Άρθρα
    • School of Medicine
    • Department of Medicine
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of PlemochoeCommunities & CollectionsTitlesAuthorsBy Issue DateSubjectsThis CollectionTitlesAuthorsBy Issue DateSubjects

    My Account

    LoginRegister

    Challenges in the diagnosis and treatment of mucormycosis

    Thumbnail
    View/Open
    Publisher version (Access full-text PDFOpen Access)
    Publisher version (Check access options)
    Check access options
    Date
    2018-04-01
    Author
    Skiada, Anna
    Lass-Floerl, Cornelia
    Klimko, Nickolay N.
    Ibrahim, Ashraf S.
    Roilides, Emmanuel J.
    Petrikkos, Georgios L.
    Metadata
    Show full item record
    Abstract
    The diagnosis and treatment of mucormycosis are challenging. The incidence of the disease seems to be increasing. Hematological malignancies are the most common underlying disease in countries with high income and uncontrolled diabetes in developing countries. Clinical approach to diagnosis lacks sensitivity and specificity. Radiologically, multiple (≥10) nodules and pleural effusion are reportedly associated with pulmonary mucormycosis. Another finding on computerized tomography (CT) scan, which seems to indicate the presence of mucormycosis, is the reverse halo sign. Microscopy (direct and on histopathology) and culture are the cornerstones of diagnosis. Molecular assays can be used either for detection or identification of mucormycetes, and they can be recommended as valuable add-on tools that complement conventional diagnostic procedures. Successful management of mucormycosis is based on a multimodal approach, including reversal or discontinuation of underlying predisposing factors, early administration of active antifungal agents at optimal doses, complete removal of all infected tissues, and use of various adjunctive therapies. Our armamentarium of antifungals is slightly enriched by the addition of two newer azoles (posaconazole and isavuconazole) to liposomal amphotericin B, which remains the drug of choice for the initial antifungal treatment, according to the recently published guidelines by ECIL-6, as well as those published by ECMM/ESCMID. Despite the efforts for better understanding of the pathogenesis, early diagnosis and aggressive treatment of mucormycosis, the mortality rate of the disease remains high.
    URI
    https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85044742791&origin=inward
    https://repo.euc.ac.cy/handle/123456789/1950
    DOI
    10.1093/mmy/myx101
    Collections
    • Department of Medicine

    entitlement

    Contact us

    Tel: +357 22 713000
    Fax: +357 22 662051
    Use contact form

    Find us

    European University Cyprus
    6, Diogenis Str., Engomi,
    P.O. Box: 22006, 1516 Nicosia-Cyprus
    View location map

    Connect with us

    Send your request to us

    Request Info
     
    • Contact us
    • Find us
    • Connect with us
    • Request Info
    © 2017 European University Cyprus, All Rights Reserved